A comprehensive understanding of the constantly evolving layers that make up federal anti-corruption statutes, sanctions regulations and export control restrictions is imperative for both the pharmaceutical and health care...more
6/16/2017
/ Anti-Corruption ,
AstraZeneca ,
Bribery ,
Bureau of Industry and Security (BIS) ,
Civil Monetary Penalty ,
Compliance ,
Corporate Misconduct ,
Cuba ,
Department of Justice (DOJ) ,
Economic Sanctions ,
Enforcement Actions ,
Export Administration Regulations (EAR) ,
Export Controls ,
Foreign Corrupt Practices Act (FCPA) ,
GlaxoSmithKline ,
Health Care Providers ,
Imports ,
Iran ,
Medical Devices ,
Novartis ,
Office of Foreign Assets Control (OFAC) ,
Open General Export Licences (OGELs) ,
Pharmaceutical Industry ,
Public Officials ,
Research and Development ,
Securities and Exchange Commission (SEC) ,
Settlement ,
Sudan ,
Teva Pharmaceuticals
As a wave of devastating ransomware-based attacks spread across the globe last week, it became abundantly clear that the medical industry at large was ill-prepared for the threat despite years of warnings. The virus hit...more